Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro

Tumor Biology

Volumn 31, Issue 6, 2010, Pages 613-622

  Chen, Jian ^a   Sun, Xiaobai ^c   Yang, Weihua ^c   Jiang, Guosheng ^c   Li, Xingang ^b  

^a JINING MEDICAL UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Adenovirous; Apoptosis; Cisplatin; Human glioma; TRAIL

Indexed keywords

ADENOVIRUS VECTOR; CASPASE 3; CISPLATIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN U251; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; FLOW CYTOMETRY; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VIRUS TITRATION;

EID: 78449235291     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-010-0077-x     Document Type: Article

References (26)

1. SR Wiley K Schooley PJ Smolak WS Din CP Huang JK Nicholl GR Sutherland TD Smith C Rauch CA Smith 1995 Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 3 673 82 1:CAS:528: DyaK28XhtF2iug%3D%3D 10.1016/1074-7613(95)90057-8 8777713
2. FA Kruyt 2008 TRAIL and cancer therapy Cancer Lett. 263 14 25 1:CAS:528:DC%2BD1cXktVCjtbs%3D 10.1016/j.canlet.2008.02.003 18329793
3. CY Kim M Jeong H Mushiake BM Kim WB Kim JP Ko MH Kim M Kim TH Kim PD Robbins TR Billiar DW Seol 2006 Cancer gene therapy using a novel secretable trimeric TRAIL Gene Ther. 13 330 8 1:CAS:528:DC%2BD28XhtFajtbk%3D 10.1038/sj.gt.3302658 16195699
4. F Yang P Shi X Xi S Yi H Li Q Sun M Sun 2006 Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC) Med Oncol. 23 191 204 1:CAS:528:DC%2BD28XlsFGrt74%3D 10.1385/MO:23:2:191 16720919
5. AP Kyritsis JS Rao VK Puduvalli 2008 Radio-responsive TRAIL gene therapy for malignant gliomas Cancer Gene Ther. 14 706 16
6. D Lawrence Z Shahrokh S Marsters K Achilles D Shih B Mounho K Hillan K Totpal L DeForge P Schow J Hooley S Sherwood S Sherwood R Pai S Leung L Khan B Gliniak J Bussiere CA Smith SS Strom S Kelley JA Fox D Thomas A Ashkenazi 2001 Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions Nat Med. 7 383 5 1:CAS:528:DC%2BD3MXis1ymtb0%3D 10.1038/86397 11283636
7. MA Grotzer A Eggert TJ Zuzak S Marwaha BR Wiewrodt N Ikegaki GM Brodeur PC Phillips 2000 Resistance to TRAIL-induced apoptosis in primitive neuroecto dermal brain tumor cells correlates with a loss of Caspase-8 expression Oncogene 19 4604 10 1:CAS:528:DC%2BD3cXnsFensLo%3D 10.1038/sj.onc.1203816 11030149
8. AM Martelli PL Tazzari G Tabellini R Bortul AM Billi L Manzoli A Ruggeri R Conte L Cocco 2003 A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells Leukemia 17 1794 805 1:CAS:528:DC%2BD3sXntFCiurw%3D 10.1038/sj.leu.2403044 12970779
9. M Nagane WK Cavenee Y Shiokawa 2007 Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human gioma cells induced by combined treatment with ionizing radiation and tumor necrosis factor-related apoptosis-inducing ligand J Neuorsurg. 106 407 16 10.3171/jns.2007.106.3.407
10. A Thorburn K Behbakht H Ford 2008 TRAIL Receptor- targeted therapeutics: Resistance mechanisms and strategies to avoid them Drug Resist Updat. 11 17 24 1:CAS:528:DC%2BD1cXlslWqtbY%3D 10.1016/j.drup.2008.02.001 18374623
11. HC Lawson P Sampath E Bohan MC Park N Hussain A Olivi J Weingart L Kleinberg H Brem 2007 Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience J Neuro-Oncol. 83 61 70 1:CAS:528:DC%2BD2sXmtVCqs7o%3D 10.1007/s11060-006-9303-1
12. G Jiang A Albihn T Tang Z Tian M Henriksson 2008 Role of Myc in differentiation and apoptosis in HL60 cells after exposure to arsenic trioxide or all-trans retinoic acid Leuk Res. 32 297 307 1:CAS:528:DC%2BD1cXitVWjtrY%3D 10.1016/j.leukres.2007.06.021 17706770
13. D Krex B Klink C Hartmann A von Deimling T Pietsch M Simon M Sabel JP Steinbach O Heese G Reifenberger M Weller G Schackert 2007 Long-term survival with glioblastoma multiforme Brain 130 2596 606 10.1093/brain/awm204 17785346
14. C Nieder M Adama M Mollsa AL Grosu 2006 Therapeutic options for recurrent high-grade glioma in adult patients: Recent advances Crit Rev Oncol Hematol. 60 181 93 10.1016/j.critrevonc.2006.06.007 16875833
15. FC Kischkel S Hellbardt I Behrmann M Germer M Pawlita PH Krammer ME Peter 1995 Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor EMBO J. 14 5579 88 1:CAS:528:DyaK2MXpslamtr4%3D 8521815
16. A Almasan A Ashkenazi 2003 Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy Cytokine Growth Factor Rev. 14 337 48 1:CAS:528:DC%2BD3sXkt1Ghs7s%3D 10.1016/S1359-6101(03)00029-7 12787570
17. H Yagita K Takeda Y Hayakawa MJ Smyth K Okumura 2004 TRAIL and its receptors as targets for cancer therapy Cancer Sci. 95 777 83 1:CAS:528:DC%2BD2cXhtFarsrbI 10.1111/j.1349-7006.2004.tb02181.x 15504243
18. RW Johnstone AJ Frew MJ Smyth 2008 The TRAIL apoptotic pathway in cancer onset, progression and therapy Nat Rev Cancer. 8 782 98 1:CAS:528: DC%2BD1cXhtFCrtbrM 10.1038/nrc2465 18813321
19. S Wang 2008 The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway Oncogene 27 6207 15 1:CAS:528:DC%2BD1cXht1GrtLvP 10.1038/onc.2008.298 18931688
20. S Translation and TRAIL Sensitivity in Glioblastoma Multiforme Cells Mol Cell Biol. 25 8809 23 1:CAS:528:DC%2BD2MXhtFWisrfP 10.1128/MCB.25.20.8809-8823.2005 16199861
21. R Rodriguez ER Schuur HY Lim GA Henderson JW Simons DR Henderson 1997 Prostate attenuated rep lication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells Cancer Res. 57 2559 63 1:CAS:528:DyaK2sXkt12ltLc%3D 9205053
22. S Frese A Schüller M Frese-Schaper M Gugger RA Schmid 2009 Cytotoxic Effects of Camptothecin and Cisplatin Combined with Tumor Necrosis Factor-related Apoptosis-inducing Ligand (Apo2L/TRAIL) in a Model of Primary Culture of Non-small Cell Lung Cancer Anticancer Res. 29 2905 12 19661294
23. A Natoni M MacFarlane S Inoue R Walewska A Majid D Knee DR Stover MJ Dyer GM Cohen 2007 RAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2 Br J Haematol. 139 568 77 1:CAS:528:DC%2BD2sXhsVyjurnL 10.1111/j.1365-2141.2007.06852.x 17922877
24. C Adida PL Crotty J McGrath D Berrebi J Diebold DC Altieri 1998 Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation Am J Pathol. 152 43 9 1:CAS:528:DyaK1cXktlygtA%3D%3D 9422522
25. S Shin BJ Sung YS Cho HJ Kim NC Ha JI Hwang CW Chung YK Jung BH Oh 2001 An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7 Biochemistry 40 1117 23 1:CAS:528:DC%2BD3MXksl2k 10.1021/bi001603q 11170436
26. S Ray S Shyam GC Fraizer A Almasan 2007 S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells Mol Cancer Ther. 6 1368 78 1:CAS:528:DC%2BD2sXktFams7s%3D 10.1158/1535-7163.MCT-05-0414 17431115